Home
/
ABVC BIOPHARMA, INC.
/
Financials
/
Quarterly
ABVC BIOPHARMA, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ABVC BIOPHARMA, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$796.0K
Nov 3, 2025
Q3
2025
Sep 30, 2024
$389.3K
Mar 3, 2026
Q2
2025
Jun 30, 2024
$117.1K
Aug 13, 2025
Q1
2025
Mar 31, 2024
$1.2K
Apr 30, 2025
Q3
2024
Sep 30, 2023
$15.9K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$6.1K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$128.3K
May 17, 2024
Q3
2023
Sep 30, 2022
$42.3K
Nov 15, 2023
Q2
2023
Jun 30, 2022
$312.9K
Aug 14, 2023
Q1
2023
Mar 31, 2022
$25.7K
May 15, 2023
Q3
2022
Sep 30, 2021
$99.0K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$31.4K
Aug 15, 2022
Q1
2022
Mar 31, 2021
$263.2K
May 16, 2022
Q3
2021
Sep 30, 2020
$115.6K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$226.5K
Aug 12, 2021
Q1
2021
Mar 31, 2020
$78.8K
May 10, 2021
Q3
2020
Sep 30, 2019
$197.7K
Nov 17, 2020
Q2
2020
Jun 30, 2019
$191.8K
Aug 14, 2020
Q1
2020
Mar 31, 2019
$212.2K
Jun 29, 2020
Q3
2019
Sep 30, 2018
$747
Nov 18, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.04M)
Mar 3, 2026
Q2
2025
Jun 30, 2025
($2.26M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($842.1K)
Apr 30, 2025
Q3
2025
Sep 30, 2024
($394.8K)
Mar 3, 2026
Q2
2025
Jun 30, 2024
($942.3K)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($2.83M)
Apr 30, 2025
Q3
2024
Sep 30, 2023
($3.32M)
Nov 14, 2024
Q2
2023
Jun 30, 2023
($2.26M)
Aug 14, 2023
Q1
2024
Mar 31, 2023
($1.82M)
May 17, 2024
Q3
2023
Sep 30, 2022
($3.70M)
Nov 15, 2023
Q2
2023
Jun 30, 2022
($1.86M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($6.00M)
May 15, 2023
Q3
2022
Sep 30, 2021
($1.81M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($1.97M)
Aug 15, 2022
Q3
2021
Jun 30, 2021
($2.05M)
Nov 15, 2021
Q1
2022
Mar 31, 2021
($1.20M)
May 16, 2022
Q3
2021
Mar 31, 2021
($1.20M)
Nov 15, 2021
Q3
2021
Sep 30, 2020
($2.13M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($2.18M)
Aug 12, 2021
Q3
2021
Jun 30, 2020
($2.18M)
Nov 15, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.96M)
Mar 3, 2026
Q2
2025
Jun 30, 2025
($2.29M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($693.0K)
Apr 30, 2025
Q3
2025
Sep 30, 2024
($302.3K)
Mar 3, 2026
Q2
2025
Jun 30, 2024
($860.1K)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($2.84M)
Apr 30, 2025
Q3
2024
Sep 30, 2023
($2.15M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($2.19M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($1.91M)
May 17, 2024
Q3
2023
Sep 30, 2022
($3.72M)
Nov 15, 2023
Q2
2023
Jun 30, 2022
($2.05M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($6.22M)
May 15, 2023
Q3
2022
Sep 30, 2021
($1.97M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($2.04M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($1.25M)
May 16, 2022
Q3
2021
Sep 30, 2020
($1.29M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($1.19M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($1.17M)
May 10, 2021
Q3
2020
Sep 30, 2019
($1.12M)
Nov 17, 2020
Q2
2020
Jun 30, 2019
($488.8K)
Aug 14, 2020